ResMed announced recently that the FDA had recently cleared its home variable positive airway pressure (VPAP) device for treatment of respiratory disorders such as chronic obstructive pulmonary disease (COPD). According to its press release, one in five patients with stage 3 or 4 COPD hospitalized for acute exacerbations are readmitted to the hospital within 30 days, but by providing better at-home care such readmissions can be avoided. Geoff Nelson, ResMed’s Respiratory Care business unit president, states in the press release that:
Minimizing the likelihood of acute events that lead to readmissions starts at the point of discharge, sending patients home with the best tools like ResMed’s VPAP COPD to help them breathe better when their lungs have been damaged by the disease.
According to the press release, ResMed’s device customizes the breath delivered to the patient with a rapid inhalation phase and an extended exhalation phase, which can help enable better gas exchange by overcoming air trapping that is common with COPD patients. ResMed’s press release is available here.